Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

2018 was a big year for industry news. Here's what might happen next in artificial intelligence, the 2020 presidential election, pharma, and more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

As merger activity heightens, some leverage retail with pharma to meet consumer demand.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Oliver Wyman
Associate, Health & Life Sciences, Oliver Wyman

Traditional retailers are now getting into the health business. What does it all mean, and where should corporate directors focus next?

Partner, Health & Life Sciences, Oliver Wyman

Health and wellness is shaping consumerism’s future. As potentially industry-shaking partnerships evolve, who’s best positioned to conquer the market?

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

With their existing customer base, brand loyalty, physical footprint, and health resources, retailers will play a significant role in offering consumers alternative sites of care.

Principal, Oliver Wyman

Insights in your inbox

Subscribe

A new Oliver Wyman survey shows how a significant portion of current healthcare spend is now poised to flow to alternative sites of care and what this means for all industry segments, from retailers to providers and payers.

Why it’s telling that a company of Target’s size and overall retail sophistication chose to exit its pharmacy business.

Principal, Oliver Wyman